Insider Trading Alert - Abercrombie & Fitch Company And 4 Others Traded By Insiders

Yesterday, July 5, 2013, 389 U.S. common stocks issued filings of shares being bought or sold by insiders. The transactions ranged in value from $200.00 to $15,089,002.16.

Highlighted Stocks Traded by Insiders:

Abercrombie & Fitch Company (ANF) - FREE Research Report

Jeffries Michael S who is Chairman and CEO at ABERCROMBIE sold 16,710 shares at $46.53 per share for a total value of $775,199.40 on July 1, 2013. Following this transaction, the Chairman and CEO owned 2.0 million shares meaning that the stake was reduced by 0.82% with the 16,710 share sell-off.

The shares most recently traded at $49.03, up $1.48, or 3.11% since the insider transaction. Historical insider transactions for Abercrombie & Fitch Company go as follows:

  • 4-Week # shares bought: 10,000
  • 4-Week # shares sold: 17,889
  • 12-Week # shares bought: 10,000
  • 12-Week # shares sold: 26,302
  • 24-Week # shares bought: 10,000
  • 24-Week # shares sold: 35,864

The average volume for Abercrombie & Fitch Company has been 1.8 million shares per day over the past 30 days. Abercrombie & Fitch Company has a market cap of $3.8 billion and is part of the services sector and retail industry. Shares are down 0.88% year to date as of the close of trading on Wednesday.

Abercrombie & Fitch Co., through its subsidiaries, operates as a specialty retailer of casual apparel for men, women, and kids. It operates through three segments: U.S. Stores, International Stores, and Direct-to-Consumer. The stock currently has a dividend yield of 1.67%. The company has a P/E ratio of 15.9. Currently there are 16 analysts that rate Abercrombie & Fitch Company a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on ANF - FREE

TheStreet Quant Ratings rates Abercrombie & Fitch Company as a buy. The company's strengths can be seen in multiple areas, such as its solid stock price performance, impressive record of earnings per share growth, compelling growth in net income, largely solid financial position with reasonable debt levels by most measures and reasonable valuation levels. We feel these strengths outweigh the fact that the company shows weak operating cash flow. Get the full Abercrombie & Fitch Company Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Millennial Media (MM) - FREE Research Report

Spilman Mary who is EVP, Global Sales & Marketing at MILLENNIAL MEDA sold 3,279 shares at $8.64 per share for a total value of $28,330.56 on July 1, 2013. Following this transaction, the EVP, Global Sales & Marketing owned 195,919 shares meaning that the stake was reduced by 1.65% with the 3,279 share sell-off.

The shares most recently traded at $8.50, up $0.32, or 3.91% since the insider transaction. Historical insider transactions for Millennial Media go as follows:

  • 4-Week # shares sold: 2,336
  • 12-Week # shares sold: 2,336
  • 24-Week # shares sold: 110,404

The average volume for Millennial Media has been 1.4 million shares per day over the past 30 days. Millennial Media has a market cap of $657.0 million and is part of the services sector and media industry. Shares are down 34.72% year to date as of the close of trading on Wednesday.

Millennial Media, Inc. provides mobile advertising solutions for advertisers and developers in the United States and internationally. The company has a P/E ratio of 51.6. Currently there are 3 analysts that rate Millennial Media a buy, no analysts rate it a sell, and 4 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on MM - FREE

TheStreet Quant Ratings rates Millennial Media as a sell. Among the areas we feel are negative, one of the most important has been a generally disappointing historical performance in the stock itself. Get the full Millennial Media Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

EXCO Resources (XCO) - FREE Research Report

Ellis Earl who is Director at EXCO RESOURCES bought 100,324 shares on July 1, 2013. Following this transaction, the Director owned 583,700 shares meaning that the stake was boosted by 20.75% with the 100,324 share acquisition.

The shares most recently traded at $8.04, down $0.00, or 0.06% since the insider transaction.

The average volume for EXCO Resources has been 3.3 million shares per day over the past 30 days. EXCO Resources has a market cap of $1.6 billion and is part of the basic materials sector and energy industry. Shares are up 18.91% year to date as of the close of trading on Wednesday.

EXCO Resources, Inc., an independent oil and natural gas company, engages in the acquisition, exploration, exploitation, development and production of onshore U.S. oil and natural gas properties with a focus on shale resource plays. The stock currently has a dividend yield of 2.69%. Currently there is 1 analyst that rates EXCO Resources a buy, 1 analyst rates it a sell, and 8 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on XCO - FREE

TheStreet Quant Ratings rates EXCO Resources as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, weak operating cash flow and generally high debt management risk. Get the full EXCO Resources Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

RenaissanceRe Holdings (RNR) - FREE Research Report

ODonnell Kevin who is Pres & Chief Executive Officer at RENAISSANCERE bought 40,468 shares on July 1, 2013. Following this transaction, the Pres & Chief Executive Officer owned 420,881 shares meaning that the stake was boosted by 10.64% with the 40,468 share acquisition.

The shares most recently traded at $85.62, up $0.38, or 0.45% since the insider transaction. Historical insider transactions for RenaissanceRe Holdings go as follows:

  • 4-Week # shares sold: 2,000
  • 12-Week # shares sold: 26,144
  • 24-Week # shares sold: 69,087

The average volume for RenaissanceRe Holdings has been 504,400 shares per day over the past 30 days. RenaissanceRe Holdings has a market cap of $3.8 billion and is part of the financial sector and insurance industry. Shares are up 4.9% year to date as of the close of trading on Wednesday.

RenaissanceRe Holdings Ltd., together with its subsidiaries, provides reinsurance and insurance coverages and related services in the United States and internationally. The stock currently has a dividend yield of 1.31%. The company has a P/E ratio of 7.4. Currently there are 6 analysts that rate RenaissanceRe Holdings a buy, no analysts rate it a sell, and 6 rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on RNR - FREE

TheStreet Quant Ratings rates RenaissanceRe Holdings as a buy. The company's strengths can be seen in multiple areas, such as its largely solid financial position with reasonable debt levels by most measures, notable return on equity, expanding profit margins, increase in stock price during the past year and growth in earnings per share. We feel these strengths outweigh the fact that the company has had sub par growth in net income. Get the full RenaissanceRe Holdings Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Celldex Therapeutics (CLDX) - FREE Research Report

Catlin Avery W who is Sr. VP & CFO at CELLDEX THERAPT bought 500 shares at $5.95 per share for a total value of $2,975.00 on July 1, 2013. Following this transaction, the Sr. VP & CFO owned 14,109 shares meaning that the stake was boosted by 3.67% with the 500 share acquisition.

Marucci Anthony S who is President & CEO at CELLDEX THERAPT bought 500 shares at $5.95 per share for a total value of $2,975.00 on July 1, 2013. Following this transaction, the President & CEO owned 43,368 shares meaning that the stake was boosted by 1.17% with the 500 share acquisition.

The shares most recently traded at $20.74, up $2.09, or 11.21% since the insider transactions.

The average volume for Celldex Therapeutics has been 1.6 million shares per day over the past 30 days. Celldex Therapeutics has a market cap of $1.5 billion and is part of the health care sector and drugs industry. Shares are up 177.94% year to date as of the close of trading on Wednesday.

Celldex Therapeutics, Inc., a biopharmaceutical company, focuses on the development, manufacture, and commercialization of novel therapeutics for human health care primarily in the United States. Currently there are 7 analysts that rate Celldex Therapeutics a buy, no analysts rate it a sell, and none rate it a hold.

Exclusive Offer: Get the latest Stock Analysis on CLDX - FREE

TheStreet Quant Ratings rates Celldex Therapeutics as a sell. The company's weaknesses can be seen in multiple areas, such as its weak operating cash flow and deteriorating net income. Get the full Celldex Therapeutics Ratings Report from TheStreet Quant Ratings now.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.

Data for this article provided by Zacks Investment Research

null

More from Markets

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Week Ahead: Trade Fears and Stress Tests Signal More Volatility To Come

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Trump Takes Aim at Auto Imports; Markets End Mixed -- ICYMI

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

Video: What Oprah's Content Partnership With Apple Means for the Rest of Tech

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

REPLAY: Jim Cramer on the Markets, Oil, Starbucks, Tesla, Okta and Red Hat

Flashback Friday: The Market Movers

Flashback Friday: The Market Movers